‘High cost of Whole Genome Sequencing (WGS) due to unregulation absence of insurance coverage acting as major restraints to market growth’, says RNCOS.

Noida, UP -- (SBWire) -- 02/05/2015 --Though the cost of WGS has been declining on a consistent basis, patients still find the service's price significantly high, especially in the case of cancer, which includes interpretation, analysis and treatment costs. Since the pricing mechanism in the personalized whole genome cancer sequencing is unregulated, private players charge different prices as per the technology used and services offered. Moreover, in the absence of insurance coverage, the out-of-pocket cost to patients fares pretty high.

In future, however, the cost of sequencing is expected to decline significantly and at a rapid pace, with experts believing it to be US$ 1,000 for an individual genome. Besides, technology upgradation will also play a crucial role in the cost reduction process.

Our report entitled "US Personalized Cancer Genome Sequencing Market Outlook 2018", entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market's growth potential for personalized cancer WGS till 2018.

The regulatory landscape has been closely monitored which requires consideration of the authorities over genome based tests. Further, we have also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. The report analyzes the competitive landscape of the market by properly analyzing the business, services and activities of the companies such as Illumina, Complete Genomics, and Ambry Genetics. It also provides the competitive benchmarking, taking into account key information such as market value, revenues, risk score etc., along with the strengths and weaknesses of each player. Overall, the report is a complete source of knowledge and statistics for clients who want to get an in-depth understanding of the market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM672.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.